Actively Recruiting
An Open Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases
Led by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Updated on 2025-06-11
37
Participants Needed
3
Research Sites
182 weeks
Total Duration
On this page
Sponsors
U
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor
N
Nanjing Legend Biotech Co.
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are investigating LCAR-AIO, a type of CAR-T cell therapy, for adults with relapsed or refractory neurological autoimmune diseases including Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disease (NMOSD), Anti-Myelin Oligodendrocyte Glycoprotein-IgG Associated Disorders (MOGAD), and Myasthenia Gravis (MG). This phase 1, open-label, single-arm study aims to explore the safety, tolerability, pharmacokinetics, and effectiveness of LCAR-AIO in these patients who have not responded well to prior treatments. Participants will receive a single infusion of LCAR-AIO CAR-T cells after a preparation process involving screening, apheresis to collect cells, and pre-treatment with lymphodepleting chemotherapy. The study includes sequential stages: screening, cell collection, cell preparation, treatment infusion, and follow-up monitoring. The infusion is given once per participant at prescribed dose levels. Throughout the study, participants will undergo assessments including monitoring for adverse events and dose-limiting toxicities, measuring CAR-T cell concentrations and gene expression levels, and evaluating clinical outcomes such as relapse rates, disability scores, visual acuity, pain levels, and functional scales related to their conditions. These evaluations will be conducted from baseline through up to 104 weeks post-infusion, allowing long-term safety and efficacy tracking. The study duration allows detailed observation and follow-up of participants after treatment.
CONDITIONS
Brief Title
A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Voluntarily agree to participate in clinical research
- Age between 18 and 70 years
- Adequate organ function at screening
- Clinical laboratory values meet criteria at screening visit
- Diagnosed with Multiple Sclerosis at least 6 months before screening and have relapsed/refractory MS
- Diagnosed with NMOSD or MOGAD at least 6 months before screening, with positive AQP-4 IgG (NMOSD) or MOG-IgG (MOGAD) by cell-based assay, and have relapsed/refractory condition
- Diagnosed with Myasthenia Gravis at least 6 months before screening, with positive AChR-IgG or MuSK-IgG, and have relapsed/refractory condition
You will not qualify if you...
- Active infections such as hepatitis or tuberculosis
- Other autoimmune diseases besides the study conditions
- Serious underlying diseases such as tumor, uncontrolled diabetes, or significant cardiovascular disease
- Female participants who are pregnant, breastfeeding, or planning pregnancy during the study or within 1 year after treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 1 to 2 days
Participants undergo apheresis to collect cells for CAR-T cell preparation.
1 visit (in-person)
Duration - Several days
Participants receive lymphodepleting chemotherapy as preparation before the CAR-T cell infusion.
Daily visits during chemotherapy days
Duration - 1 day
Participants receive a single infusion of LCAR-AIO CAR-T cells as the active treatment for their neurological autoimmune disease.
1 infusion visit (in-person)
Duration - Up to 104 weeks
Participants are monitored up to 104 weeks after infusion to evaluate safety, efficacy, and long-term outcomes.
Regular follow-up visits during 2 years post-treatment
Trial Site Locations
Total: 3 locations
1
The Affiliated Hospital of Fujian Medical University
Fuzhou, China
Not Yet Recruiting
2
The First Affiliated Hospital of SOOCHOW University
Suzhou, China
Actively Recruiting
3
Union Hospital Tongji Medical College HUAZHONG University of Science and Technology
Wuhan, China
Actively Recruiting
Research Team
Q
Qiubai li
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here